|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-2.00/-64.88
|
企業價值
36.09M
|
資產負債 |
每股賬面淨值
-0.79
|
現金流量 |
現金流量率
--
|
損益表 |
收益
12.00M
|
每股收益
0.53
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/05/21 17:19 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
ASLAN Pharmaceuticals Ltd is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. The Company's major business is research and development and operates only in one single segment. |